Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Other Non-Current Assets (2020 - 2025)

Maxcyte (MXCT) has disclosed Other Non-Current Assets for 6 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 61.03% to $2.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Dec 2025, up 61.03% year-over-year, with the annual reading at $2.5 million for FY2025, 61.03% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $2.5 million at Maxcyte, down from $2.6 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $2.8 million in Q2 2025, with the low at $295000.0 in Q1 2024.
  • Average Other Non-Current Assets over 5 years is $1.1 million, with a median of $920500.0 recorded in 2022.
  • The sharpest move saw Other Non-Current Assets skyrocketed 834.22% in 2021, then plummeted 62.15% in 2023.
  • Over 5 years, Other Non-Current Assets stood at $316700.0 in 2021, then skyrocketed by 155.45% to $809000.0 in 2022, then crashed by 52.04% to $388000.0 in 2023, then soared by 294.85% to $1.5 million in 2024, then soared by 61.03% to $2.5 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $2.5 million, $2.6 million, and $2.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.